Attempt at putting what we know about #BTK resistance mutations into one figure..

Beware inducing cross-resistant L528Wmuts pre ncBTKi.

#hemesky #hematology #lymsm #hemepath #NGS

pubmed.ncbi.nlm.nih.gov/39808800/

Therapy related myeloid neoplasm post CART in DLBCL arises from TP53 clones identifiable preCART… but high baseline incidence of TP53/PPM1D CH preCART.. so the challenge is identifying those with clones that will progress - Zhi Han Yeoh from @petermaccc.bsky.social. #ASH24 #hemepath #hemesky #lymsm

Very interesting R-CHOP+X session (or Pola-R-CHP+X..) in DLBCL. 3/6 presentations in the session with data presented on ctDNA MRD!.. including the COALITION study (Adrian Minson/ @drmikedickinson.bsky.social. CtDNA helpful in resolving nature of EOT PET abnormalities #ASH24 #lymsm #hemesky #hemepath

Dr. Jacoby from Washington University on intervening in AML based on mut clearance at 2.5% VAF across exome level in a variant agnostic way. Great to see this “fingerprint” MRD approach being used in trials.. lots of analogies to current lymphoma ctDNA space #hemepath #hemesky #leusm #lymsm #ASH24

Exciting to see the first results from the INTERCEPT platform study (PI Andrew Wei) expertly presented by Dr. Sun Loo from @petermaccc.bsky.social at #ASH24. Intervening with a molecularly rational approach at early #MRD relapse is feasible in AML and the results with revumenib are encouraging.

Dr. Ing Soo Tiong from @petermaccc.bsky.social presenting his excellent work at #ASH24 on how the remission clonal haematopoietic landscape is shaped by venetoclax in pts with AML. TP53 and BAX microclones! With a bit more sensitive sequencing tech we will find the nanoclones… #hemepath #hemesky

A great (in-person!) meeting of the MM-VCEP #ClinGen group today at #ASH24. Lots of exciting projects and milestones for the group on the horizon including making rules for new genes (SAMD9/SAMD9L/TERT/TERC..) as well as progress on our DDX41 curation rules. Stay tuned..

Loss of function TET2 germline variants.. potentially a lot more common than previously thought.. Well done to Sean Harrop presenting our work on this emerging immune dysregulatory syndrome in the germline BMF workshop at #ASH24 #hemepath #hemesky